Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBIT (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of EBIT readings, the most recent being -$101.5 million for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 287.96% year-over-year to -$101.5 million, compared with a TTM value of $5.1 million through Dec 2025, up 103.07%, and an annual FY2025 reading of $5.1 million, up 103.07% over the prior year.
  • EBIT hit -$101.5 million in Q4 2025 for Apellis Pharmaceuticals, down from $223.2 million in the prior quarter.
  • The five-year high for EBIT was $293.7 million in Q4 2022, with the low at -$194.3 million in Q2 2021.
  • Median EBIT over the past 5 years was -$95.5 million (2021), compared with a mean of -$67.5 million.
  • The largest YoY upside for EBIT was 572.05% in 2025 against a maximum downside of 287.96% in 2025.
  • Year by year, EBIT stood at -$89.4 million in 2021, then skyrocketed by 428.56% to $293.7 million in 2022, then tumbled by 128.77% to -$84.5 million in 2023, then soared by 69.04% to -$26.2 million in 2024, then plummeted by 287.96% to -$101.5 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$101.5 million, $223.2 million, and -$33.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.